pembrolizumab fda approval endometrial cancer

Keyword Analysis

Keyword	CPC	PCC	Volume	Score	Length of keyword
pembrolizumab fda approval endometrial cancer	0.94	0.2	1102	66	45
pembrolizumab	0.95	1	8562	55	13
fda	0.5	0.2	2944	17	3
approval	0.98	0.2	816	74	8
endometrial	0.85	0.4	8159	61	11
cancer	0.75	0.9	8946	14	6

Keyword	CPC	PCC	Volume	Score
pembrolizumab fda approval endometrial cancer	1.58	0.9	4883	37
pembrolizumab in advanced endometrial cancer	0.98	0.8	151	12
pembrolizumab for endometrial cancer	1.97	0.2	3603	35
pembrolizumab chemotherapy endometrial cancer	1.21	1	7748	96
pembrolizumab fda approval breast cancer	0.15	0.9	5750	39
pembrolizumab endometrial cancer nejm	0.53	0.8	6536	66
fda approval pembrolizumab cervical cancer	1.13	0.5	5130	90
pembrolizumab gastric cancer fda approval	0.61	0.9	9793	83
pembrolizumab first line endometrial cancer	1.78	0.8	706	83
pembrolizumab breast cancer approval	0.19	0.7	9576	3
pembrolizumab ovarian cancer approval	0.4	1	6552	42
pembrolizumab cervical cancer approval	0.25	1	7633	96
pembrolizumab lung cancer fda approval	0.09	0.3	5695	1
pembrolizumab fda approval history	1.28	0.6	837	79
pembrolizumab bladder cancer approval	0.46	0.8	2102	80
pembrolizumab fda approval melanoma	1.6	0.3	8272	56
pembrolizumab mesothelioma fda approval	0.55	0.2	3555	4
pembrolizumab lenvatinib endometrial cancer	0.42	0.2	8876	32
nice pembrolizumab endometrial cancer	0.51	0.5	4216	47
when was pembrolizumab fda approved	1.67	0.5	5161	56
pembrolizumab fda label 2022	0.22	0.6	1811	39
pembrolizumab for breast cancer	1.51	0.4	4440	31